美諾華(603538.SH):擬以5.37億元轉讓燎原藥業84.57%股權
格隆匯5月4日丨美諾華(603538.SH)公佈,公司憑藉在化學小分子CDMO領域的持續深耕佈局,已打造了CDMO業務一站式服務能力和體系,具備卓越的研發生產服務承接能力。同時,公司擁有豐富的高規格的原料藥、中間體產能。
以江西濟民可信集團有限公司為首的濟民可信集團是中國知名的現代化大健康產業集團,連續多年名列中國醫藥工業百強前十。目前濟民可信集團正積極佈局創新藥研發,目前已擁有20多款在研1類新藥,有較大CDMO產能需求;同時基於濟民可信集團發展戰略,有獲取自有原料藥、中間體生產基地的需求。
雙方本着“資源共享、優勢互補、互惠雙贏、共同發展”的原則,濟民可信集團擬將公司作為其創新藥CDMO領域的重要合作伙伴,與公司在創新藥研發和生產等方面開展合作。
出於公司自身產能結構優化、加速戰略升級轉型需求考慮,公司與江西濟民可信醫藥產業投資有限公司(“濟民可信投資”)於2022年5月1日在浙江省寧波市簽署了《戰略合作暨股權轉讓框架協議》。公司擬將持有的浙江燎原藥業股份有限公司(“燎原藥業”)84.57%股權以交易對價537,019,500元轉讓給濟民可信投資,以滿足其對原料藥、中間體產能的需求。
此次交易對價537,019,500元系基於燎原藥業截至2021年12月31日財務報表情況及對其未來發展的預期,經交易雙方協商擬定,若此交易對價低於後續評估機構出具的《資產評估報吿》中交易標的評估值,交易雙方將另行協商交易對價。上述股權轉讓事項完成後,公司將不再持有燎原藥業的股權,燎原藥業不再納入公司合併報表範圍。
此次股權轉讓預計產生投資收益24106.29萬元,扣除所得税影響、擬轉讓標的原預計歸屬於母公司淨利潤貢獻約600萬元等因素,預計合計增加歸屬於母公司的淨利潤17479.72萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.